Satoshi Obara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Satoshi Obara has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi B. Tsuji
Department of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology (QST), Chiba
43 shared publications Aya Sugyo
43 shared publications- Didier Boturyn
Univ. Grenoble Alpes, CNRS, DCM (UMR 5250), F-38000 Grenoble, France
43 shared publications Hidekatsu Wakizaka
43 shared publicationsKotaro Nagatsu
43 shared publicationsKuan Hu
43 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Spatial relationship of intratumoral Cy5.5-RaftRGD to the tumor microenvironment (magnified images)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Spatial relationship of intratumoral Cy5.5-RaftRGD to the tumor microenvironment (magnified images)
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Supplementary Materials and Methods for integrin expression analysis, autoradiography, ITD of Cy5.5-RaftRGD in relation to the tumor microenvironment (in s.c. tumors), PET/CT or PET/CECT imaging and quantification, Ki-67 immunostaining, TUNEL assay, and quantification, survival study, and toxicity evaluation.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Supplementary Materials and Methods for integrin expression analysis, autoradiography, ITD of Cy5.5-RaftRGD in relation to the tumor microenvironment (in s.c. tumors), PET/CT or PET/CECT imaging and quantification, Ki-67 immunostaining, TUNEL assay, and quantification, survival study, and toxicity evaluation.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S12 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Correlation between tumor length (mm) and tumor weight (g)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Correlation between tumor length (mm) and tumor weight (g)
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S16 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
64Cu-RaftRGD-based TRT (toxicity evaluation: hepatorenal functions and gastrointestinal state)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
64Cu-RaftRGD-based TRT (toxicity evaluation: hepatorenal functions and gastrointestinal state)
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Integrin expression in OVCAR-3 and IGR-OV1 s.c. xenografts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Integrin expression in OVCAR-3 and IGR-OV1 s.c. xenografts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S13 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Proliferation and morphology of small intestine and kidney at 3 days after i.p. administration of 148 MBq/0.357 nmol 64Cu-RaftRGD
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Proliferation and morphology of small intestine and kidney at 3 days after i.p. administration of 148 MBq/0.357 nmol 64Cu-RaftRGD
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Spatial relationship of intratumoral Cy5.5-RaftRGD to the tumor microenvironment (detailed images for s.c. xenografts)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Spatial relationship of intratumoral Cy5.5-RaftRGD to the tumor microenvironment (detailed images for s.c. xenografts)
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S18 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Reducing effect of Gelofusine and L-lysine on the renal accumulation of 64Cu-RaftRGD
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S18 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Reducing effect of Gelofusine and L-lysine on the renal accumulation of 64Cu-RaftRGD
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Microscopic examination of ascites
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Microscopic examination of ascites
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
PET quantification and post-PET biodistribution of 64Cu-RaftRGD (OVCAR-3-OCPM mice)
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
PET quantification and post-PET biodistribution of 64Cu-RaftRGD (OVCAR-3-OCPM mice)